- Home
- FTFT vs THAR Comparison
FTFT vs THAR Comparison
Compare FTFT & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTFT
- THAR
- Stock Information
- Founded
- FTFT N/A
- THAR 2017
- Country
- FTFT United States
- THAR United States
- Employees
- FTFT N/A
- THAR N/A
- Industry
- FTFT Business Services
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- FTFT Consumer Discretionary
- THAR Health Care
- Exchange
- FTFT Nasdaq
- THAR Nasdaq
- Market Cap
- FTFT 3.9M
- THAR 3.3M
- IPO Year
- FTFT N/A
- THAR 2022
- Fundamental
- Price
- FTFT $1.17
- THAR $1.51
- Analyst Decision
- FTFT
- THAR Strong Buy
- Analyst Count
- FTFT 0
- THAR 1
- Target Price
- FTFT N/A
- THAR $17.00
- AVG Volume (30 Days)
- FTFT 154.6K
- THAR 26.3K
- Earning Date
- FTFT 05-20-2025
- THAR 05-12-2025
- Dividend Yield
- FTFT N/A
- THAR N/A
- EPS Growth
- FTFT N/A
- THAR N/A
- EPS
- FTFT N/A
- THAR N/A
- Revenue
- FTFT $2,031,913.00
- THAR N/A
- Revenue This Year
- FTFT N/A
- THAR N/A
- Revenue Next Year
- FTFT N/A
- THAR N/A
- P/E Ratio
- FTFT N/A
- THAR N/A
- Revenue Growth
- FTFT N/A
- THAR N/A
- 52 Week Low
- FTFT $1.06
- THAR $0.95
- 52 Week High
- FTFT $7.77
- THAR $6.39
- Technical
- Relative Strength Index (RSI)
- FTFT 35.84
- THAR 54.61
- Support Level
- FTFT $1.46
- THAR $1.41
- Resistance Level
- FTFT $1.57
- THAR $1.64
- Average True Range (ATR)
- FTFT 0.14
- THAR 0.11
- MACD
- FTFT -0.04
- THAR 0.01
- Stochastic Oscillator
- FTFT 15.07
- THAR 63.86
About FTFT Future FinTech Group Inc.
Future FinTech Group Inc is engaged in the financial technology business. The company participates in supply chain financing services and trading in China, asset management business in Hong Kong, and cross-border money transfer services in the United Kingdom. It has also expanded into brokerage and investment banking business in Hong Kong and cryptocurrency mining farm in the U.S. The company's reportable segments include the Supply chain financing/trading segment which generates key revenue, and the Asset management service segment.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.